Effects of cancer drugs on survival: often poorly evaluated.
(1) Overall survival is the gold-standard endpoint when evaluating the efficacy of cancer drugs; (2) Progression-free survival is an endpoint that combines two very different components: death or objective worsening of the tumour. It is a heterogeneous endpoint and measurement of the second component is imprecise. There are few examples where a correlation has been established between progression-free survival and overall survival; (3) Time to progression is an endpoint of limited interest: it only takes into account the second component of the progression-free survival composite endpoint; (4) Disease-free survival is a variant of progression-free survival and is most frequently used for adjuvant treatments.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015982:Bias; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D018450:Disease Progression; D018572:Disease-Free Survival; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis
D000970:Antineoplastic Agents